The health care sector is experiencing unprecedented times, coupled with staff shortages and high levels of unenrolled patients. We are all in the same waka. City Medical Napier has proposed a quarterly forum of the urgent care centres across Aotearoa New Zealand, where we can sit around the virtual table and share our challenges and…
A new audio interview series featuring health care professionals and researchers involved in trauma care and rehabilitation has been published on the Te Tāhū Hauora Health Quality & Safety Commission website. Called Trauma Exchange, the interviews are of interest to anyone involved in trauma care and rehabilitation. They cover a range of topics: State of…
ANZCA’s Gender Equity Subcommittee is hosting a free webinar Words matter: inclusive language in gender diverse care on Thursday 12 October at 6 PM AEDT. The webinar will discuss inclusive language to create safer interactions with gender diverse communities in healthcare. It features guest speaker Hannah Maher, policy writer and LGBTQ+ Inclusive Practice trainer from…
Kia ora koutou, The theme for Aotearoa Patient Safety Day 2023 is ‘Engaging patients for patient safety’ with the tagline ‘Elevate the voice of patients’. Resources are available to order now; more information about how to place your order is below. Te Tāhū Hauora Health Quality & Safety Commission is using Aotearoa Patient Safety Day…
Dear Colleagues, tēnā koutou katoa, My name is Albert Wu, I am a FRNZCGP and am currently working as the Medical Administration Registrar at Counties Manukau. I would like your opinion on rationalising the primary care inbox to streamline paperwork, as your time is valuable. All clinically active and training General Practitioners, Urgent Care Physicians,…
On Tuesday 22nd of August Dr Paul Huggan, an Infectious Disease Specialist from Waikato and co-founder of the NZ Sepsis Trust presented a webinar for the Goodfellow Unit on recognising sepsis in primary care. The recording of the webinar is available below. This is valuable CPD for urgent care physicians. https://www.goodfellowunit.org/events-and-webinars/sepsis-how-not-miss-it-primary-care
Free Professional Development eLearning module opportunities Last year the HDC launched a series of online learning modules to improve providers’ knowledge and understanding of people’s health and disability rights. These three free modules cover how the Code of Rights improves health and disability services, what you need to know about informed consent, and complaints management…
Author: Dr Gareth Norton
Date: August 2022
Abstract:
Croup, or laryngotracheobronchitis, is an extremely common presentation of respiratory
disease in the paediatric population. The mainstay of treatment is oral corticosteroids and in moderate/severe cases nebulised adrenaline. Concerns exist around the possibility of a rebound effect where their are increased symptoms when the effect of a drug has passed. If a drug produces a rebound effect, the condition it was used to treat may return with an
increased severity. Or is there no rebound effect and the return of symptoms, even at an
increased severity is due to the natural course and progression of the treated condition?
Author: Dr Gustav Fourie
2019
Abstract:
Hypertension is a common presentation but there is no New Zealand based guideline for the management of severe asymptomatic hypertension (greater than 180 systolic or 110 diastolic) in urgent care. Definitions have varied in both naming ( hypertensive emergency, hypertensive urgency, hypertensive crisis ,malignant hypertension,accelerated hypertension, severe asymptomatic hypertension) and parameters.
Method:
A review of recent literature was conducted.
Author: Dr Gary Mitchell
Abstract:
Rivaroxaban is well established as a treatment for deep vein thrombosis and pulmonary embolism, but there has been hesitation in using it as a bridging agent in clinical situations where DVT is suspected but not yet confirmed by definitive ultrasound scan. The evidence for the safety and efficacy of this approach is explored. During this time of research, the use of rivaroxaban began to gain acceptance and usage in New Zealand, leading to a brief analysis of factors involved in trying to introduce up to date guidelines into a small health organisation in New Zealand prior to widespread acceptance and definitive guidelines at District Health Board level.